Anti-TNF-α and anti-CD-20 drugs have demonstrated a limited benefit in the control of systemic manifestations, while the CTLA fusion protein (CTLA4), abatacept, seems to bring hope in the alleviation of musculoskeletal manifestations of pSS patients [89,90,91]. This evidence concerns the gene TNF and peeling skin syndrome.